[The renin-angiotensin-aldosterone system -- more complex as previously thought]
- PMID: 16096728
- PMCID: PMC7079980
- DOI: 10.1007/s00063-005-1071-8
[The renin-angiotensin-aldosterone system -- more complex as previously thought]
Abstract
Background: Angiotensin II (ANG II) is an important factor for the progression of renal diseases. ANG II has many pleiotropic effects on the kidney such as pro-inflammatory and profibrotic actions besides the well-known blood pressure-increasing effect.
Novel knowledge: Organs have local ANG II-generating systems that work independently from their classic systemic counterpart. Renal proximal tubular cells could generate and secrete ANG II into the urine in concentrations that are 10,000 times higher than those found in serum. These local systems are only incompletely blocked by currently used doses of ACE inhibitors or AT(1) antagonists. There are other enzyme systems besides ACE that contribute to the formation of ANG II. Alternative pathways generate peptides such as angiotensin 1-7 that have antagonistic effect compared with ANG II. Degradation products of ANG II such as angiotensin IV bind at separate receptors and could mediate fibrosis. The discovery of AT(1) receptor dimers and agonistic antibodies against AT(1) receptors contributes to the complexity of the system.
Clinical relevance: The complexity of the renin-angiotensin-aldosterone system (RAAS) implies that dual blockade with ACE inhibitors and AT(1) receptor antagonists makes sense for pathophysiological reasons. First clinical studies have shown that such as dual therapy reduces progression of chronic renal disease more efficiently that the respective monotherapies in certain risk populations. This shows that novel pathophysiological data could lead to innovative clinical treatment strategies.
Angiotensin II (ANG II) ist ein wichtiger Faktor für das Fortschreiten von Nierenerkrankungen. Neben der bekannten blutdrucksteigernden Wirkung hat ANG II eine Vielzahl von pleiotropen Effekten wie proinflammatorische und profibrogene Wirkungen auf die Niere.
Organe haben lokale ANG–II–generierende Systeme, die vom klassischen endokrinen Renin–Angiotensin–Aldosteron–System (RAAS) völlig unabhängig sind. So können beispielsweise proximale Tubuluszellen der Niere in den Primärharn ANG–II–Konzentrationen abgeben, die bis zu 10 000fach über dem Serumspiegel liegen. Diese lokalen Systeme werden durch Standarddosen von ACE–Hemmern oder AT1–Blockern nur unvollständig gehemmt. Es gibt neben ACE auch andere Enzymsysteme, die ANG II generieren können. Durch alternative Stoffwechselwege können Peptide erzeugt werden, die wie Angiotensin 1–7 gegenteilige Wirkung im Vergleich zu ANG II haben. Abbauprodukte von ANG II wie Angiotensin IV binden an separate Rezeptoren und können Fibrose initiieren. Die Entdeckung von AT1–Rezeptor–Dimeren und agonistischen Antikörpern kompliziert das System zusätzlich.
Aufgrund der Komplexität des RAAS ist aus pathophysiologischen Überlegungen heraus eine Doppelblockade des Systems mit ACE–Hemmern wie auch AT1–Rezeptor–Antagonisten sinnvoll. Erste Studien haben gezeigt, dass in bestimmten Risikopopulationen die Progression der chronischen Niereninsuffizienz durch eine solche Doppelblockade im Vergleich zur Monotherapie signifikant verlangsamt werden kann. Dies zeigt, dass neue pathophysiologische Erkenntnisse Eingang in die Klinik finden.
Similar articles
-
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.Kidney Int. 2005 Mar;67(3):799-812. doi: 10.1111/j.1523-1755.2005.00145.x. Kidney Int. 2005. PMID: 15698420 Review.
-
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].Presse Med. 2002 Nov 9;31(36):1714-20. Presse Med. 2002. PMID: 12467154 Review. French.
-
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.Kidney Int. 2005 Nov;68(5):2189-96. doi: 10.1111/j.1523-1755.2005.00675.x. Kidney Int. 2005. PMID: 16221218
-
Hypertension: renin-angiotensin-aldosterone system alterations.Circ Res. 2015 Mar 13;116(6):960-75. doi: 10.1161/CIRCRESAHA.116.303587. Circ Res. 2015. PMID: 25767283 Review.
-
Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.J Manag Care Pharm. 2004 Sep;10(5 Suppl A):S12-7. doi: 10.18553/jmcp.2004.10.S5-A.S12. J Manag Care Pharm. 2004. PMID: 15369420 Free PMC article. Review.
Cited by
-
The effect of angiotensin II and IV on ERK1/2 and CREB signalling in cultured rat astroglial cells.Naunyn Schmiedebergs Arch Pharmacol. 2007 Nov;376(3):157-63. doi: 10.1007/s00210-007-0192-4. Epub 2007 Oct 19. Naunyn Schmiedebergs Arch Pharmacol. 2007. PMID: 17952409
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous